[Phase III clinical trial of KRN8601 (rhG-CSF) for neutropenia in patients with human immunodeficiency virus infection].
The efficacy of KRN8601 for neutropenia associated with HIV infection was evaluated in 24 patients. KRN8601 was infused intravenously at a dosage of 200 micrograms/m2 for 14 consecutive days. Neutrophil counts recovered in 19 (90.5%) out of 21 evaluable patients by KRN8601 treatment. The concomitant myelosuppressive agents for the treatment of HIV infection and complications could be continued without dose reduction in 15 (88.2%) out of 17 patients. The clinical improvement was observed in 66.7% (12/18) of patients who were treated with anti-microbial agents for opportunistic infections which indicates that KRN8601 shows an additive effect on infections when it was given with anti-microbial agents. Adverse events and abnormal laboratory findings were observed in 3 and 7 patients, respectively, and they were reversible and tolerable. This study demonstrated that KRN8601 improved neutropenia with HIV infection, made possible to continue the full dose of myelosuppressive treatments and have additive effect on the treatment of secondary infections.
Department of Infection Diseases and Applied Immunology, University of Tokyo.
S
S
Kimura
K
K
Shimada
J
J
Matsuda
K
K
Gohchi
K
K
Fukutake
H
H
Fukue
T
T
Okubo
Y
Y
Ishigatsubo
K
K
Yamada
Y
Y
Koitabashi
D000293:Adolescent; D000328:Adult; D002360:Carubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology
C053537:morpholinoanthracycline MX2; D002360:Carubicin